Immunological and virological status of a hemophiliac infected with human T cell lymphotropic virus type 1 and human immunodeficiency virus type 1, and results of therapy.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Immunological and virological status of a hemophiliac infected with human T cell lymphotropic virus type 1 and human immunodeficiency virus type 1, and results of therapy.

Int J Hematol. 1991 Feb;54(1):85-90. Unique Identifier : AIDSLINE MED/92062983
Murakami T; Hattori T; Maeda Y; Matsushita S; Kannagi M; Sagawa K; Takatsuki K; Second Department of Internal Medicine, Kumamoto University; Medical School, Japan.

Abstract: The immunological and virological status of three hemophiliacs infected with human immunodeficiency virus type 1 (HIV-1) was monitored for 11 months. One of these patients was also infected with human T cell lymphotropic virus type 1 (HTLV-1), and HIV-1 could be isolated only from this patient among the three subjects. The doubly infected subject had the fewest T4 (helper) lymphocytes and the highest proportion of T8 lymphocytes with DR human leukocyte antigens (DR-Ag). The serum level of HIV-1 antigen increased in this patient during the observation period, and this increase was accompanied by a decrease in the proportion of DR-Ag-positive cells among the T8 lymphocytes. This patient was treated with 800 mg of zidovudine daily for 50 days. With treatment, the nonspecific clinical symptoms improved and the proportions of DR-Ag positive cells among the T8 lymphocytes decreased. Serum levels of HIV-1 antigen decreased immediately when therapy was started but later increased during therapy. In persons infected with both HTLV-1 and HIV-1, HIV-1 seems to proliferate readily.

Keywords: Adolescence Adult Christmas Disease/COMPLICATIONS/DRUG THERAPY/*IMMUNOLOGY/ MICROBIOLOGY Hemophilia/COMPLICATIONS/DRUG THERAPY/*IMMUNOLOGY/MICROBIOLOGY Human HIV Infections/COMPLICATIONS/DRUG THERAPY/*IMMUNOLOGY/ MICROBIOLOGY HTLV-I Infections/COMPLICATIONS/DRUG THERAPY/*IMMUNOLOGY/ MICROBIOLOGY Support, Non-U.S. Gov't Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE

920330
M9230718

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .